UBS Group’s Foamix Pharmaceuticals FOMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-2,427
Closed -$8K – 8792
2019
Q4
$8K Sell
2,427
-8,826
-78% -$28.1K ﹤0.01% 7420
2019
Q3
$34K Buy
11,253
+10,253
+1,025% +$28.8K ﹤0.01% 6423
2019
Q2
$2K Sell
1,000
-1,413
-59% -$4.22K ﹤0.01% 7674
2019
Q1
$9K Sell
2,413
-1,730,584
-100% -$6.48M ﹤0.01% 6911
2018
Q4
$6.22M Buy
1,732,997
+1,725,874
+24,230% +$7.51M ﹤0.01% 1970
2018
Q3
$41K Buy
7,123
+2,187
+44% +$12.5K ﹤0.01% 6313
2018
Q2
$25K Buy
4,936
+3,936
+394% +$20.3K ﹤0.01% 6554
2018
Q1
$5K Sell
1,000
-297
-23% -$1.79K ﹤0.01% 7273
2017
Q4
$8K Sell
1,297
-4,670
-78% -$28.1K ﹤0.01% 7188
2017
Q3
$34K Buy
5,967
+4,967
+497% +$25.7K ﹤0.01% 6085
2017
Q2
$5K Hold
1,000
– – ﹤0.01% 7157
2017
Q1
$5K Sell
1,000
-615
-38% -$5.92K ﹤0.01% 7026
2016
Q4
$18K Sell
1,615
-1,014
-39% -$9.5K ﹤0.01% 6594
2016
Q3
$25K Buy
2,629
+1,152
+78% +$9.6K ﹤0.01% 6116
2016
Q2
$9K Sell
1,477
-1,834
-55% -$12.2K ﹤0.01% 6864
2016
Q1
$22K Buy
3,311
+1,536
+87% +$9.9K ﹤0.01% 6144
2015
Q4
$15K Buy
1,775
+333
+23% +$2.49K ﹤0.01% 7028
2015
Q3
$11K Sell
1,442
-8,210
-85% -$83.7K ﹤0.01% 7223
2015
Q2
$99K Buy
9,652
+6,795
+238% +$75.1K ﹤0.01% 5417
2015
Q1
$26K Buy
+2,857
New +$25.6K ﹤0.01% 6710

UBS Group's FOMX Position: Q1 2020 in Review

UBS Group sold out of Foamix Pharmaceuticals (FOMX) in Q1 2020, closing a stake of 2,427 shares — an estimated $8K sold.

UBS Group first reported a position in FOMX in Q1 2015 and held it in 20 quarters. The position peaked at $6.22M in Q4 2018. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

  • UBS Group reported no remaining Foamix Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • UBS Group sold 2,427 Foamix Pharmaceuticals shares in Q1 2020, an estimated $8K.
  • UBS Group first reported a position in Foamix Pharmaceuticals in Q1 2015 and held it in 20 quarters.
  • UBS Group's Foamix Pharmaceuticals position peaked at $6.22M in Q4 2018.
  • 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.